{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:49:52Z","timestamp":1791582592947,"version":"4.3.4"},"reference-count":215,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitors have revolutionized the treatment of solid tumors; however, their clinical efficacy remains limited to a subset of patients. Novel immunotherapy agents are being investigated in phase I clinical trials, with an increasing focus on biomarker selection strategies to optimize patient outcomes. Prior evidence suggests that biomarker-selected tumors may have better outcomes when treated with molecularly-guided therapies. However, the high complexity of tumor-host interactions and inter-patient variability indicates that a one-size-fits-all biomarker approach is unlikely to be sufficient in the immunotherapy landscape. This review highlights current biomarker-enrichment strategies in immunotherapy early drug development, addressing challenges and potential future directions for their effective implementation.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1664443","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:32:50Z","timestamp":1761111170000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Optimizing early-phase immunotherapy trials: the role of biomarker enrichment strategies"],"prefix":"10.3389","volume":"16","author":[{"given":"Greta","family":"Catani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Morch\u00f3n-Araujo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"Mirallas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"S\u00e1nchez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Nuciforo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Villacampa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Dienstmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Vivancos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Garralda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Hernando-Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.01.035","article-title":"Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape","volume":"81","author":"Emens","year":"2017","journal-title":"Eur J Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1741","article-title":"Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1","volume":"23","author":"Champiat","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3133","article-title":"Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate","volume":"23","author":"Kato","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djab066","article-title":"Wedding of molecular alterations and immune checkpoint blockade: genomics as a matchmaker","volume":"113","author":"Fountzilas","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_160766","article-title":"Biomarkers for immunotherapy: current developments and challenges","author":"Spencer","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26115394","article-title":"Emerging immunotherapy targets in early drug development","volume":"26","author":"Morch\u00f3n-Araujo","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1530","article-title":"Facts and hopes on biomarkers for successful early clinical immunotherapy trials: innovative patient enrichment strategies","volume":"30","author":"Cannarile","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/biostatistics\/kxx069","article-title":"Estimation of clinical trial success rates and related parameters","volume":"20","author":"Wong","year":"2019","journal-title":"Biostatistics"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/1740774515625964","article-title":"Key cost drivers of pharmaceutical clinical trials in the United States","volume":"13","author":"Sertkaya","year":"2016","journal-title":"Clin Trials"},{"key":"B14","doi-asserted-by":"publisher","first-page":"112927","DOI":"10.1016\/j.ejca.2023.05.015","article-title":"Correlation between biomarkers and treatment outcomes in diverse cancers: a systematic review and meta-analysis of phase I and II immunotherapy clinical trials","volume":"189","author":"Fountzilas","year":"2023","journal-title":"Eur J Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733","article-title":"Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.12000","article-title":"Association of high tissue TMB and atezolizumab efficacy across multiple tumor types","volume":"36","author":"Legrand","year":"2018","journal-title":"JCO"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA approval summary: Pembrolizumab for the treatment of tumor mutational burden-high solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"B21","volume-title":"List of Cleared or Approved Companion Diagnostic Devices (","year":"2025"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0599-y","article-title":"Immune checkpoint inhibitors for the treatment of MSI-H\/MMR-D colorectal cancer and a perspective on resistance mechanisms","volume":"121","author":"Sahin","year":"2019","journal-title":"Br J Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-023-01499-4","article-title":"Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity","volume":"55","author":"Westcott","year":"2023","journal-title":"Nat Genet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1172\/JCI122095","article-title":"Polymerase-mediated ultramutagenesis in mice produces diverse cancers with high mutational load","volume":"128","author":"Li","year":"2018","journal-title":"J Clin Invest"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Sade-Feldman","year":"2017","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.21873\/invivo.12131","article-title":"Association between the efficacy of pembrolizumab and low STK11\/LKB1 expression in high-PD-L1-expressing non-small-cell lung cancer","volume":"34","author":"Hasegawa","year":"2020","journal-title":"In Vivo"},{"key":"B29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.21037\/atm.2019.11.52Kato","article-title":"Pan-cancer analysis of KEAP1 mutations as biomarkers for immunotherapy outcomes","volume":"8","author":"Chen","year":"2020","journal-title":"Ann Transl Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1-14","DOI":"10.1200\/PO.17.00235","article-title":"Analysis of MDM2 amplification: next-generation sequencing of patients with diverse Malignancies","volume":"2018","author":"Kato","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12929-024-01004-x","article-title":"Targeting MDM2 in Malignancies is a promising strategy for overcoming resistance to anticancer immunotherapy","volume":"31","author":"Sun","year":"2024","journal-title":"J BioMed Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of PTEN promotes resistance to T cell-mediated immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discov"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11010190","article-title":"Wnt\/\u03b2-catenin signaling and resistance to immune checkpoint inhibitors: from non-small-cell lung cancer to other cancers","volume":"11","author":"Muto","year":"2023","journal-title":"Biomedicines"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.908752","article-title":"Predictive biomarkers of severe immune-related adverse events with immune checkpoint inhibitors: prevention, underlying causes, intensity, and consequences","volume":"9","author":"Carde\u00f1a-Guti\u00e9rrez","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1301","article-title":"The future of clinical trial design in oncology","volume":"11","author":"Spreafico","year":"2021","journal-title":"Cancer Discov"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3146","article-title":"PD-L1 studies across tumor types, its differential expression and predictive value in patients treated with immune checkpoint inhibitors","volume":"23","author":"Kluger","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14010109","article-title":"Comparative analysis of predictive biomarkers for PD-1\/PD-L1 inhibitors in cancers: developments and challenges","volume":"14","author":"Yang","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2015.11.001","article-title":"Predictive biomarkers in PD-1\/PD-L1 checkpoint blockade immunotherapy","volume":"41","author":"Meng","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12340","article-title":"PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1\/PD-L1 clinical trials","volume":"28","author":"Madore","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.06.014","article-title":"Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer","volume":"35","author":"Di Federico","year":"2024","journal-title":"Ann Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.lungcan.2020.08.020","article-title":"Re-biopsy after first line treatment in advanced NSCLC can reveal changes in PD-L1 expression","volume":"149","author":"Frank","year":"2020","journal-title":"Lung Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.12929","article-title":"Clinical significance of \u2265 50% PD-L1 expression with the SP263 monoclonal antibody in non-small cell lung cancer patients","volume":"10","author":"Li","year":"2019","journal-title":"Thorac Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.04.026","article-title":"Programmed death-ligand 1 heterogeneity and its impact on benefit from immune checkpoint inhibitors in NSCLC","volume":"15","author":"Hong","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.05.001","article-title":"Five year survival update from KEYNOTE-010: Pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1-positive advanced NSCLC","volume":"16","author":"Herbst","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomized, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"B50","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"KEYNOTE-859 investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.11.012","article-title":"Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study","volume":"36","author":"Andr\u00e9","year":"2025","journal-title":"Ann Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402141","article-title":"Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer","volume":"391","author":"Andre","year":"2024","journal-title":"N Engl J Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00914","article-title":"First-line pembrolizumab + Chemotherapy versus placebo + Chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826","volume":"41","author":"Monk","year":"2023","journal-title":"J Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103972","article-title":"Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial","volume":"9","author":"Rosenberg","year":"2024","journal-title":"ESMO Open"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33033","article-title":"Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial","volume":"126","author":"Motzer","year":"2020","journal-title":"Cancer"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3390\/jmp2030018","article-title":"Modern challenges for early-phase clinical trial design and biomarker discovery in metastatic non-small-cell lung cancer","volume":"2","author":"Rossi","year":"2021","journal-title":"J Mol Pathol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4191","article-title":"Classification and characterization of microsatellite instability across 18 cancer types","volume":"22","author":"Hause","year":"2016","journal-title":"Nat Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"20003","DOI":"10.1038\/s41598-021-99364-z","article-title":"Concordance analysis of microsatellite instability status between polymerase chain reaction based testing and next generation sequencing for solid tumors","volume":"11","author":"Shimozaki","year":"2021","journal-title":"Sci Rep"},{"key":"B65","doi-asserted-by":"publisher","first-page":"97","DOI":"10.23750\/abm.v89i9-S.7960","article-title":"Microsatellite instability in colorectal cancer","volume":"89","author":"De' Angelis","year":"2018","journal-title":"Acta Biomed"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100120","article-title":"Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer","volume":"6","author":"Guyot D'Asni\u00e8res De Salins","year":"2021","journal-title":"ESMO Open"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00648","article-title":"Analysis of concordance between next-generation sequencing assessment of microsatellite instability and immunohistochemistry-mismatch repair from solid tumors","volume":"8","author":"Ali-Fehmi","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/nrc3816","article-title":"Hypermutation in human cancer genomes: footprints and mechanisms","volume":"14","author":"Roberts","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"B69","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s13046-022-02422-1","article-title":"POLE\/POLD1 mutation and tumor immunotherapy","volume":"41","author":"Ma","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B70","volume-title":"Approval Timeline of Active Immunotherapies","year":"2025"},{"key":"B71","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41571-025-01015-z","article-title":"Epidemiology, pathogenesis, biology and evolving management of MSI-H\/dMMR cancers","volume":"22","author":"Ambrosini","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00932-9","article-title":"Tumour mutational burden: clinical utility, challenges and emerging improvements","volume":"21","author":"Budczies","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0522","article-title":"Tumor mutational burden as a predictive biomarker in solid tumors","volume":"10","author":"Sha","year":"2020","journal-title":"Cancer Discov"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31878","article-title":"Size matters: dissecting key parameters for panel-based tumor mutational burden analysis","volume":"144","author":"Buchhalter","year":"2019","journal-title":"Int J Cancer"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000147","article-title":"Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project","volume":"8","author":"Merino","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.01.023","article-title":"Harmonization and standardization of panel-based tumor mutational burden measurement: real-world results and recommendations of the Quality in Pathology Study","volume":"15","author":"Stenzinger","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-012","article-title":"Association of tumor mutational burden with efficacy of pembrolizumab \u00b1 chemotherapy as first-line therapy for gastric cancer in the phase III KEYNOTE-062 study","volume":"28","author":"Lee","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31257-1","article-title":"Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial","volume":"392","author":"Shitara","year":"2018","journal-title":"Lancet"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.11.015","article-title":"Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: results from a single-arm, phase II study in patients with \u226525% tumour cell PDL1 expression who have progressed on platinum-based chemotherapy","volume":"107","author":"Zandberg","year":"2019","journal-title":"Eur J Cancer"},{"key":"B80","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1001\/jamaoncol.2018.4628","article-title":"Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1-low\/ negative recurrent or metastatic HNSCC: the phase 2 CONDOR randomized clinical trial","volume":"5","author":"Siu","year":"2019","journal-title":"JAMA Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2765","article-title":"Tumor mutational burden as a predictor of survival with durvalumab and\/or tremelimumab treatment in recurrent or metastatic head and neck squamous cell carcinoma","volume":"29","author":"Wildsmith","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1929","article-title":"TAS-116 (Pimitespib), an oral HSP90 inhibitor, in combination with nivolumab in patients with colorectal cancer and other solid tumors: an open-label, dose-finding, and expansion phase Ib trial (EPOC1704)","volume":"27","author":"Kawazoe","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010311","article-title":"Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types","volume":"13","author":"Gandara","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non-small-cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N Engl J Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3771","article-title":"A blood-based assay for assessment of tumor mutational burden in first-line metastatic NSCLC treatment: Results from the MYSTIC study","volume":"27","author":"Si","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01933-w","article-title":"Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial","volume":"28","author":"Peters","year":"2022","journal-title":"Nat Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.0014","article-title":"Tissue-plasma TMB comparison and plasma TMB monitoring in patients with metastatic non-small cell lung cancer receiving immune checkpoint inhibitors","volume":"10","author":"Friedlaender","year":"2020","journal-title":"Front Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.2963","article-title":"Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002797","article-title":"Distinct mutational profile and immune microenvironment in microsatellite-unstable and POLE-mutated tumors","volume":"9","author":"Hwang","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B94","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41392-024-01939-5","article-title":"A phase II clinical trial of toripalimab in advanced solid tumors with polymerase epsilon\/polymerase delta (POLE\/POLD1) mutation","volume":"9","author":"Jin","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.5952","article-title":"Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study","volume":"35","author":"Ott","year":"2017","journal-title":"J Clin Oncol"},{"key":"B96","unstructured":"Multicenter prospective cohort of tumors with POLE\/POLD1 mutation\n          \n          \n          \n          2024"},{"key":"B97","unstructured":"A single-arm, open, multicenter phase II study of chemotherapy-sequential tislelizumab adjuvant therapy after radical resection in patients with gastric or colorectal adenocarcinoma with dMMR\/MSI-H or POLE\/POLD1 mutations\n          \n          \n          2023"},{"key":"B98","unstructured":"A phase II open label study of toripalimab, a PD-1 antibody, in participants with POLE or POLD-1 mutated and non-MSI-H advanced solid tumors\n          \n          \n          2023"},{"key":"B99","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1158\/2159-8290.CD-12-0361","article-title":"ARID1A mutations in cancer: another epigenetic tumor suppressor","volume":"3","author":"Wu","year":"2013","journal-title":"Cancer Discov"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx277","article-title":"Immune-active microenvironment in small cell carcinoma of the ovary, hypercalcemic type: rationale for immune checkpoint blockade","volume":"110","author":"Jelinic","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"B101","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/s41467-021-21068-9","article-title":"Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma","volume":"12","author":"Bakouny","year":"2021","journal-title":"Nat Commun"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2022.03.003","article-title":"All is not lost: learning from 9p21 loss in cancer","volume":"43","author":"Spiliopoulou","year":"2022","journal-title":"Trends Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx271","article-title":"Tumor CDKN2A-associated JAK2 loss and susceptibility to immunotherapy resistance","volume":"110","author":"Horn","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"B104","doi-asserted-by":"publisher","first-page":"5606","DOI":"10.1038\/s41467-021-25894-9","article-title":"9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy","volume":"12","author":"Han","year":"2021","journal-title":"Nat Commun"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf8399","article-title":"Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy","volume":"355","author":"Davoli","year":"2017","journal-title":"Science"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aah3560","article-title":"Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance","volume":"9","author":"Roh","year":"2017","journal-title":"Sci Transl Med"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000417","article-title":"B2M and JAK1\/2-mutated MSI-H colorectal carcinomas can benefit from anti-PD-1 therapy","volume":"45","author":"Zhang","year":"2022","journal-title":"J Immunother"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1439","article-title":"Hypermutated circulating tumor DNA: correlation with response to checkpoint inhibitor-based immunotherapy","volume":"23","author":"Khagi","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2014.222679","article-title":"Circulating tumor DNA as a liquid biopsy for cancer","volume":"61","author":"Heitzer","year":"2015","journal-title":"Clin Chem"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx026","article-title":"Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma","volume":"28","author":"Lee","year":"2017","journal-title":"Ann Oncol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-0096-5","article-title":"Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab","volume":"1","author":"Bratman","year":"2020","journal-title":"Nat Cancer"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.2510","article-title":"Prognostic and predictive value of ultrasensitive ctDNA monitoring in a metastatic pan-cancer cohort treated with immune checkpoint inhibitors in the context of phase 1 clinical trials [Abstract","volume":"42","author":"De Almeida Toledo","year":"2024","journal-title":"JCO"},{"key":"B113","unstructured":"Use of circulating tumor deoxyribonucleic acid for early-stage solid tumor drug development: guidance for industry\n          \n          \n          \n          2024"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00181","article-title":"Impact of circulating tumor DNA\u2013based detection of molecular residual disease on the conduct and design of clinical trials for solid tumors","author":"Kasi","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0380-z","article-title":"Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study","volume":"25","author":"Rothwell","year":"2019","journal-title":"Nat Med"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1324","article-title":"Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel","volume":"25","author":"Willis","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005344","article-title":"Regulatory implications of ctDNA in immuno-oncology for solid tumors","volume":"11","author":"Vellanki","year":"2023","journal-title":"J ImmunoTher Cancer"},{"key":"B118","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13046-025-03328-4","article-title":"A perspective review on the systematic implementation of ctDNA in phase I clinical trial drug development","volume":"44","author":"Guigal-Stephan","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00372","article-title":"Changes in circulating tumor DNA reflect clinical benefit across multiple studies of patients with non-small-cell lung cancer treated with immune checkpoint inhibitors","volume":"6","author":"Vega","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.603157","article-title":"Emerging blood-based biomarkers for predicting response to checkpoint immunotherapy in non-small-cell lung cancer","volume":"11","author":"Li","year":"2020","journal-title":"Front Immunol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"key":"B122","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13046-021-01872-3","article-title":"Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity","volume":"40","author":"Relecom","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-019-0022-x","article-title":"Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy","volume":"1","author":"Valpione","year":"2020","journal-title":"Nat Cancer"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12092146","article-title":"The importance of predictive biomarkers and their correlation with the response to immunotherapy in solid tumors\u2014Impact on clinical practice","volume":"12","author":"Mihaila","year":"2024","journal-title":"Biomedicines"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.180","article-title":"Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients","volume":"112","author":"Ferrucci","year":"2015","journal-title":"Br J Cancer"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.07.024","article-title":"Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab","volume":"111","author":"Diem","year":"2017","journal-title":"Lung Cancer"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11030432","article-title":"Validation of neutrophil count as an algorithm-based predictive factor of progression-free survival in patients with metastatic soft tissue sarcomas treated with trabectedin","volume":"11","author":"de Nonneville","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02706-5","article-title":"Post-treatment neutrophil-to-lymphocyte ratio (NLR) predicts response to anti-PD-1\/PD-L1 antibody in SCLC patients at early phase","volume":"70","author":"Xiong","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-04023-w","article-title":"Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival","volume":"85","author":"Ota","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30020187","article-title":"The prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma","volume":"30","author":"Parosanu","year":"2023","journal-title":"Curr Oncol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.585271","article-title":"Systemic immune-inflammation index and changes of neutrophil-lymphocyte ratio as prognostic biomarkers for patients with pancreatic cancer treated with immune checkpoint blockade","volume":"11","author":"Shang","year":"2021","journal-title":"Front Oncol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010928","article-title":"Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols","volume":"13","author":"Cottrell","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2023.106364","article-title":"Nutritional status associates with immunotherapy clinical outcomes in recurrent or metastatic head and neck squamous cell carcinoma patients","volume":"140","author":"Hernando-Calvo","year":"2023","journal-title":"Oral Oncol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-020-02420-9","article-title":"Dynamics of clinical biomarkers as predictors of immunotherapy benefit in metastatic melanoma patients","volume":"23","author":"Hernando-Calvo","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2015.1043026","article-title":"Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies","volume":"54","author":"Petrelli","year":"2015","journal-title":"Acta Oncol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000531","article-title":"Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors","volume":"4","author":"Iivanainen","year":"2019","journal-title":"ESMO Open"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.2559","article-title":"C-reactive protein as a response biomarker to immune checkpoint blockade: A meta-analysis","volume":"41","author":"Fujiwara","year":"2023","journal-title":"J Clin Oncol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007765","article-title":"Early kinetics of C reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: a multicenter cohort study","volume":"11","author":"Barth","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkad027","article-title":"Early C-reactive protein kinetics predicts immunotherapy response in non-small cell lung cancer in the phase III OAK trial","volume":"7","author":"Saal","year":"2023","journal-title":"JNCI Cancer Spectr"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2015.3","article-title":"Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25","volume":"25","author":"Hannani","year":"2015","journal-title":"Cell Res"},{"key":"B141","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/82_2010_51","article-title":"STAT3: a target to enhance antitumor immune response","volume":"344","author":"Lee","year":"2011","journal-title":"Curr Top Microbiol Immunol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1093722","article-title":"Cytokine patterns in cancer patients: A review of the correlation between interleukin 6 and prognosis","volume":"5","author":"Lippitz","year":"2016","journal-title":"Oncoimmunology"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.4110\/in.2020.20.e27","article-title":"Baseline serum interleukin-6 levels predict the response of patients with advanced non-small cell lung cancer to PD-1\/PD-L1 inhibitors","volume":"20","author":"Kang","year":"2020","journal-title":"Immune Netw"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.670391","article-title":"The role of cytokines in predicting the response and adverse events related to immune checkpoint inhibitors","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107692","article-title":"Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression","volume":"219","author":"Fousek","year":"2021","journal-title":"Pharmacol Ther"},{"key":"B146","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1158\/2326-6066.CIR-16-0206","article-title":"Angiopoietin-2 as a biomarker and target for immune checkpoint therapy","volume":"5","author":"Wu","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0163","article-title":"Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab","volume":"2","author":"Yuan","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-23-566","article-title":"The role of laboratory tests as a prognostic marker for immune-checkpoint therapy in non-small cell lung cancer","volume":"12","author":"Ashok Kumar","year":"2023","journal-title":"Transl Lung Cancer Res"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17122001","article-title":"Blood-based biomarkers as predictive and prognostic factors in immunotherapy-treated patients with solid tumors\u2014currents and perspectives","volume":"17","author":"Kaczmarek","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-019-00736-0","article-title":"Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials","volume":"37","author":"Martini","year":"2019","journal-title":"Invest New Drugs"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0281","article-title":"Prolonged benefit from ipilimumab correlates with improved outcomes from subsequent pembrolizumab","volume":"4","author":"Shreders","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15133490","article-title":"The effectiveness of cancer immune checkpoint inhibitor retreatment and rechallenge\u2014a systematic review","volume":"15","author":"Perdyan","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1475502","article-title":"Efficacy and safety of immune checkpoint inhibitors rechallenge in advanced solid tumors: a systematic review and meta-analysis","volume":"14","author":"Cao","year":"2024","journal-title":"Front Oncol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00079","article-title":"Pembrolizumab plus ipilimumab following anti-PD-1\/L1 failure in melanoma","volume":"39","author":"Olson","year":"2021","journal-title":"J Clin Oncol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02498-y","article-title":"Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial","volume":"29","author":"VanderWalde","year":"2023","journal-title":"Nat Med"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115161","article-title":"Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11\/GNAQ mutant melanocytic tumors","volume":"214","author":"Dimitriou","year":"2025","journal-title":"Eur J Cancer"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.1186","article-title":"Practice patterns and survival outcomes of immunotherapy for metastatic colorectal cancer","volume":"8","author":"Bari","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14184481","article-title":"Real-world outcomes and treatments patterns prior and after the introduction of first-line immunotherapy for the treatment of metastatic non-small cell lung cancer","volume":"14","author":"Danesi","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00735-6","article-title":"Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study","volume":"26","author":"Long","year":"2025","journal-title":"Lancet Oncol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1171","article-title":"Impact of prior treatment on the efficacy of adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma","volume":"27","author":"Seitter","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.2586","article-title":"Clinical outcomes in phase 1 clinical trials (Ph1-CT) when treating patients (pts) with novel immunotherapy (IT) agents at early lines for advanced disease","volume":"41","author":"Soto","year":"2023","journal-title":"J Clin Oncol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1323151","article-title":"Refining patient selection for next-generation immunotherapeutic early-phase clinical trials with a novel and externally validated prognostic nomogram","volume":"15","author":"Losurdo","year":"2024","journal-title":"Front Immunol"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.2187","article-title":"Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab","volume":"5","author":"Topalian","year":"2019","journal-title":"JAMA Oncol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.08.026","article-title":"Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents","volume":"139","author":"Tarantino","year":"2020","journal-title":"Eur J Cancer"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.18416","article-title":"Clinical response to immunotherapy targeting programmed cell death receptor 1\/programmed cell death ligand 1 in patients with treatment-resistant microsatellite stable colorectal cancer with and without liver metastases","volume":"4","author":"Wang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.4240\/wjgs.v16.i6.1513","article-title":"Immunotherapy in gastric cancer with liver metastasis: challenges and opportunities","volume":"16","author":"Bardak\u00e7i","year":"2024","journal-title":"World J Gastrointest Surg"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03083-7","article-title":"Botensilimab plus balstilimab in relapsed\/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial","volume":"30","author":"Bullock","year":"2024","journal-title":"Nat Med"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat Med"},{"key":"B169","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41698-025-00812-0","article-title":"Progress in personalized immunotherapy for patients with brain metastasis","volume":"9","author":"Patel","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01713","article-title":"Microenvironmental regulation of tumor progression and therapeutic response in brain metastasis","volume":"10","author":"Schulz","year":"2019","journal-title":"Front Immunol"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.04.021","article-title":"Systemic and intracranial outcomes with first-line nivolumab plus ipilimumab in patients with metastatic NSCLC and baseline brain metastases from CheckMate 227 Part 1","volume":"18","author":"Reck","year":"2023","journal-title":"J Thorac Oncol"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05680-3","article-title":"Single-cell spatial immune landscapes of primary and metastatic brain tumours","volume":"614","author":"Karimi","year":"2023","journal-title":"Nature"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00566-3","article-title":"Phenotypic diversity of T cells in human primary and metastatic brain tumors revealed by multiomic interrogation","volume":"4","author":"Wischnewski","year":"2023","journal-title":"Nat Cancer"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1281645","article-title":"Immune-related adverse events and their effects on survival outcomes in patients with non-small cell lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"14","author":"Liang","year":"2024","journal-title":"Front Oncol"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"B177","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12916-020-01549-2","article-title":"Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis","volume":"18","author":"Zhou","year":"2020","journal-title":"BMC Med"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.100787","article-title":"Immune-related adverse events as potential surrogates of immune checkpoint inhibitors' efficacy: a systematic review and meta-analysis of randomized studies","volume":"8","author":"Amoroso","year":"2023","journal-title":"ESMO Open"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol"},{"key":"B180","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.molonc.2008.12.002","article-title":"Biomarkers in oncology drug development","volume":"3","author":"Hodgson","year":"2009","journal-title":"Mol Oncol"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.04.012","article-title":"PD-L1-overexpressing NSCLC: overcoming all-comer approach and network effect to weather the \"Winter\" of cancer immunotherapy","volume":"20","author":"Salomone","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B182","doi-asserted-by":"crossref","DOI":"10.17226\/13297","volume-title":"Evolution of Translational Omics: Lessons Learned and the Path Forward","author":"Micheel","year":"2012"},{"key":"B183","doi-asserted-by":"publisher","first-page":"1-12","DOI":"10.1200\/PO.19.00068","article-title":"Developing and validating risk assessment models of clinical outcomes in modern oncology","volume":"3","author":"Halabi","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"B184","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/09332480.2019.1695438","article-title":"Advancing precision oncology through biomarker-driven trials: theory vs. practice","volume":"32","author":"Halabi","year":"2019","journal-title":"Chance"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1177\/1740774510368574","article-title":"Predictive biomarker validation in practice: lessons from real trials","volume":"7","author":"Mandrekar","year":"2010","journal-title":"Clin Trials"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.01.161","article-title":"Biomarker discovery and validation: statistical considerations","volume":"16","author":"Ou","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2011.4","article-title":"Biomarker studies: a call for a comprehensive biomarker study registry","volume":"8","author":"Andre","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"B188","unstructured":"Critical impacts of IVDR implementation on patient access to clinical trials\n          \n          \n          \n          2022"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2023.03.014","article-title":"Genomic and proteomic biomarker landscape in clinical trials","volume":"21","author":"Pi\u00f1ero","year":"2023","journal-title":"Comput Struct Biotechnol J"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","volume":"351","author":"Paik","year":"2004","journal-title":"N Engl J Med"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.05.069","article-title":"Integrated proteogenomic characterization of human high-grade serous ovarian cancer","volume":"166","author":"Zhang","year":"2016","journal-title":"Cell"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.387","article-title":"Progresses in biomarkers for cancer immunotherapy","volume":"4","author":"Lin","year":"2023","journal-title":"MedComm (2020)"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00739","article-title":"Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I\/II checkMate 358 trial","volume":"37","author":"Naumann","year":"2019","journal-title":"J Clin Oncol"},{"key":"B194","doi-asserted-by":"publisher","first-page":"A1","DOI":"10.1136\/jitc-2022-SITC2022.1477","article-title":"1477 First efficacy and multi-omic analysis data from phase 1 clinical trial of oncolytic viral immunotherapy with CAN-2409 + valacyclovir in combination with nivolumab and standard of care in newly diagnosed high-grade glioma","volume":"10","author":"Wen","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-1089","article-title":"Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma","volume":"69","author":"Hoshida","year":"2009","journal-title":"Cancer Res"},{"key":"B196","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.medj.2023.07.006","article-title":"A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials","volume":"4","author":"Hernando-Calvo","year":"2023","journal-title":"Med"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02385-6","article-title":"Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495\/KeyImPaCT trial interim results","volume":"29","author":"Gutierrez","year":"2023","journal-title":"Nat Med"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2014.12.003","article-title":"Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types","volume":"9","author":"Lebofsky","year":"2015","journal-title":"Mol Oncol"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1395332","article-title":"Exosomal PD-L1 in cancer and other fields: recent advances and perspectives","volume":"15","author":"Lu","year":"2024","journal-title":"Front Immunol"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2020.03.002","article-title":"Exosomal PD-L1: roles in tumor progression and immunotherapy","volume":"6","author":"Morrissey","year":"2020","journal-title":"Trends Cancer"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2024.103111","article-title":"Spatial omics techniques and data analysis for cancer immunotherapy applications","volume":"87","author":"Zhang","year":"2024","journal-title":"Curr Opin Biotechnol"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.687673","article-title":"Highly multiplexed phenotyping of immunoregulatory proteins in the tumor microenvironment by CODEX tissue imaging","volume":"12","author":"Phillips","year":"2021","journal-title":"Front Immunol"},{"key":"B203","doi-asserted-by":"publisher","first-page":"16994","DOI":"10.1038\/s41598-023-43435-w","article-title":"Fully automated sequential immunofluorescence (seqIF) for hyperplex spatial proteomics","volume":"13","author":"Rivest","year":"2023","journal-title":"Sci Rep"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0534","article-title":"Patient-centric approaches for phase I combination trials come on stage","volume":"13","author":"Hernando-Calvo","year":"2023","journal-title":"Cancer Discov"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1002\/mp.13678","article-title":"Machine and deep learning methods for radiomics","volume":"47","author":"Avanzo","year":"2020","journal-title":"Med Phys"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101487","article-title":"Microbiome bacterial influencers of host immunity and response to immunotherapy","volume":"5","author":"Yousefi","year":"2024","journal-title":"Cell Rep Med"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14864","article-title":"Microbiome modulates immunotherapy response in cutaneous squamous cell carcinoma","volume":"32","author":"Voigt","year":"2023","journal-title":"Exp Dermatol"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0066","article-title":"Randomized placebo-controlled, biomarker-stratified phase Ib microbiome modulation in melanoma: impact of antibiotic preconditioning on microbiome and immunity","volume":"14","author":"Glitza","year":"2024","journal-title":"Cancer Discov"},{"key":"B209","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1146\/annurev-pharmtox-022724-095035","article-title":"Next-gen therapeutics: pioneering drug discovery with iPSCs, genomics, AI, and clinical trials in a dish","volume":"65","author":"Yildirim","year":"2025","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"B210","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.annonc.2023.10.125","article-title":"Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review","volume":"35","author":"Prelaj","year":"2024","journal-title":"Ann Oncol"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03398-5","article-title":"Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data","volume":"31","author":"Yoo","year":"2025","journal-title":"Nat Med"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.03.029","article-title":"AI-driven predictive biomarker discovery with contrastive learning to improve clinical trial outcomes","volume":"43","author":"Arango-Argoty","year":"2025","journal-title":"Cancer Cell"},{"key":"B213","unstructured":"Integrating change in ctDNA levels in advanced cancer clinical trials to support meta-analyses for intermediate endpoint validation\n          \n          \n          \n          2024"},{"key":"B214","unstructured":"Use of circulating tumor DNA for early-stage solid tumor drug development: guidance for industry\n          \n          \n          \n          2022"},{"key":"B215","unstructured":"Service description, conformity assessment procedures according to Regulation (EU) 2017\/746 on in-vitro diagnostic medical devices (IVDR)\n          \n          \n          2017"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1664443\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:32:56Z","timestamp":1761111176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1664443\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":215,"alternative-id":["10.3389\/fimmu.2025.1664443"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1664443","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"article-number":"1664443"}}